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Background: Most non-dialysis dependent chronic kidney disease (CKD) patients are cared for by their primary care
physicians (PCPs). Studies suggest many CKD patients receive suboptimal care. Recently, CKD clinical practice
guidelines were updated with additional emphasis on albuminuria.
Methods: We performed an internet-based, cross-sectional survey of active PCPs in the United States using the
American Medical Association Physician Masterfile. We explored CKD guideline familiarity, self-reported practice
behaviors, and attitudinal and external barriers to implementing guideline recommendations, including albuminuria
testing.
Results: Of 12,034 PCPs targeted, 848 opened a study email, 165 (19.5%) responded. Most respondents (88%) spent ≥50%
of their time in clinical care. Respondents were generally in private practice (46%). Most PCPs (96%) felt that
eGFR values were helpful. Approximately, 75% and 91% of PCPs reported testing for albuminuria in non-diabetic
hypertensive patients with an eGFR > 60 ml/min/1.73 m2 and < 60 ml/min/1.73 m2, respectively. Barriers to albuminuria
testing included a lack of effect on management, limited time, and the perceived absence of guidelines recommending
testing. While PCPs expressed high levels of agreement with the definition of CKD, 30% were concerned with
overdiagnosis in older adults with an eGFR in the CKD stage 3a range. Most PCPs felt that angiotensin converting
enzyme inhibitor (ACEi)/ angiotensin II receptor blockers (ARBs) improved outcomes in CKD, though agreement
was lower with severe vs. moderate albuminuria (78% vs. 85%, respectively, p = 0.03). Many PCPs (51%) reported
being unfamiliar with CKD guidelines, but were receptive to systematic interventions to improve their CKD care.
Conclusions: PCPs generally agree with CKD clinical practice guidelines regarding CKD definition and albuminuria
testing. However, future interventions are necessary to improve PCPs’ familiarity with CKD guidelines, overcome
barriers to albuminuria testing and, assist PCPs in targeting ACEi/ARBs to the patients most likely to benefit.
Keywords: Chronic kidney disease, Primary care physicians, Survey, Estimate glomerular filtration rate,
Albuminuria, Angiotensin converting enzyme inhibitors, Angiotensin II receptor blockers, BarriersBackground
Chronic kidney disease (CKD) affects millions of Americans
[1] and estimates suggest that over 50% of adults in the
United States (US) will develop CKD during their life-
time [2]. Primary care providers (PCPs) deliver the
majority of non-dialysis dependent CKD care and this* Correspondence: khaled.abdel-kader@vanderbilt.edu
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article, unless otherwise stated.trend is expected to continue due to limitations in the
nephrologist workforce [3].
Multiple studies have documented deficiencies in PCP
delivery of CKD care. These include suboptimal screening/
monitoring of patients with CKD risk factors [4,5], infre-
quent discussions between providers and patients regard-
ing CKD [6], suboptimal albuminuria testing in CKD
patients [7,8], suboptimal blood pressure control [9],
and suboptimal renin-angiotensin blockade in CKD pa-
tients with proteinuria [10,11]. In light of these deficien-
cies, studies have also demonstrated shortcomings inntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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awareness of Kidney Disease Outcomes Quality Initia-
tive (KDOQI) clinical practice guidelines [14-17].
Recently, Kidney Disease Improving Global Outcomes
(KDIGO) released updated CKD clinical practice guide-
lines [18]. For PCPs, perhaps the most salient modification
is the emphasis on albuminuria as a risk stratification
marker for poor outcomes. We employed the knowledge,
attitudes, and behavior framework adapted by Cabana [19]
to study reasons for PCP non-adherence to key compo-
nents of the 2012 KDIGO CKD guidelines (i.e., assessing
estimated glomerular filtration rate [eGFR] and albumin-
uria/proteinuria, definition of CKD, and use of angiotensin
converting enzyme inhibitor [ACEi] or angiotensin II re-
ceptor blockers [ARBs] in overtly albuminuric/proteinuric
patients) [18], focusing on non-diabetic CKD. We chose
to concentrate on non-diabetic CKD because several stud-
ies have noted superior PCP performance in diabetic CKD
(including albuminuria quantification and ACEi/ARB use)
and high rates of familiarity with the American Diabetic
Association’s clinical practice guidelines [7,12,20]. We also
assessed interventions PCPs would find most acceptable
to optimize CKD care.
Methods
Study design, population, and setting
We performed a web-based, cross-sectional survey of US
PCPs between April and June 2013. We identified PCPs
actively practicing in the US and included in the American
Medical Association’s (AMA) Physician Masterfile. We emailed
a simple random sample of 12,034 PCPs for this survey.
Questionnaire design and content
The questionnaire included items assessing PCPs’ know-
ledge, beliefs, attitudes, self-reported behavior, and per-
ceived barriers regarding aspects of CKD care as well
as demographic and practice characteristics. Questions
were developed following appraisal of the literature (KA)
[6-11,13-19,21-30]. An internist and nephrologist with
domain and survey expertise revised the questionnaire
(RG, MU). We subsequently pilot-tested the questionnaire
among 16 community- and hospital-based internists and
family practitioners. We revised the questionnaire based
on feedback. Several items (e.g., regarding cystatin C) were
universally unfamiliar to PCPs and were removed from
the survey. We then formatted the questionnaire for web-
based administration and pilot tested the web-based ques-
tionnaire among 5 additional PCPs who had not reviewed
previous versions.
Because studies indicate that PCPs are more likely to
recognize, evaluate, and treat diabetic CKD [5,7,31],
and given the added emphasis on albuminuria in the
new guidelines [18], we focused questionnaire items on
non-diabetic CKD and on the assessment, recognition,and treatment of albuminuria in non-diabetic CKD care.
The final questionnaire featured both vignette-based
and non-vignette based multiple choice questions with
33 items concerning CKD (see Additional file 1 for full
questionnaire).
The initial items followed a vignette of a 73-year-old
white man with well controlled hypertension treated with
amlodipine and hydrochlorothiazide who presented for
routine follow-up. The patient had a normal history and
exam and an elevation in serum creatinine and decrement
in eGFR that progressed over 12 months (1.3 mg/dl to
1.4 mg/dl and 55 ml/min/1.73 m2 to 50 ml/min/1.73 m2,
respectively). We designed the vignette to simulate a com-
mon scenario that has raised concerns regarding CKD
overdiagnosis due to age-related decline in kidney func-
tion [23,32-36]. Subsequent questions featured a 4-point
Likert scale (ranging from strongly agree to strongly
disagree, with a 5th option for “Don’t Know”) to assess
participants’ agreement with statements regarding the
utility of eGFR, further testing with quantitative albumin-
uria or urinalysis, perceived limitations of urine testing
due to patient burden or poor test reliability, and the pres-
ence of CKD in the described patient. Later questions
more directly assessed concerns for overdiagnosis in pa-
tients with a stable eGFR between 45–59 ml/min/1.73 m2
and 30–44 ml/min/1.73 m2.
We also assessed how frequently (ranging from twice
a year to never/rarely) PCPs reported testing for urine
albumin/protein in non-diabetic hypertensives and poten-
tial barriers to urine testing. PCPs could select multiple
barriers including patient level (e.g., cost, adherence), en-
vironmental (e.g., limited time), and attitudinal (e.g., lack
of outcome expectancy) barriers.
In two items, we provided PCPs with an intersecting
grid of albuminuria and eGFR values to assess their be-
liefs regarding (a) the presence of CKD in a 65 year-old
non-diabetic patient and (b) whether ACEi/ARBs would
improve outcomes in a non-diabetic patient with the
specified test results (e.g., Figure 1). These grids repre-
sented abbreviated versions of the 2012 KDIGO CKD
classification system [18] and respondents used a drop
down menu in each cell to choose their response (i.e.,
“yes”, “no”, or “unsure”). We also assessed patient level,
environmental, and attitudinal barriers to ACEi/ARB use
in non-diabetics with “macroalbuminuria”.
We assessed PCPs’ familiarity and perceived helpfulness
of the KDOQI/KDIGO guidelines and their potential
interest in interventions to optimize CKD care. We also
collected information on PCPs’ demographics and practice
characteristics.
Survey implementation
We sent broadcast emails in 2 waves. To maximize
responses [37], we sent PCPs a personally addressed
Figure 1 PCPs reporting that a non-diabetic older adult with the specified characteristics has CKD. Colors indicate CKD risk categories as
classified in KDIGO guidelines. yellow – moderate, orange – high, red – very high. N = 154.
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versity affiliations as well as a statement regarding the
importance of the topic. We sent PCPs a personally ad-
dressed email invitation several days later. The invita-
tion included a link to the web-based questionnaire and
disclosed a 1-week deadline for completion. The subject
heading for the broadcast emails did not mention “sur-
vey” or “questionnaire” (e.g., “Assessing the potential
impact of CKD staging changes”). Emails contained
statements ensuring the confidentiality of respondents
and offering a $20 electronic gift card for participation.
We ascertained the opened status of emails by encoding
a pixel in the messages that communicated when an
email was opened. We gave survey recipients 21 days to
open and/or respond to the email. The University of
Pittsburgh Institutional Review Board approved this
study.Statistical analysis
We described questionnaire responses using descriptive
statistics. We collapsed Likert scales into 3 categories:
strongly agree/agree, strongly disagree/disagree, and don’t
know. Chi-square or Fisher’s exact test was used to assess
independence of categorical variables as appropriate. We
employed multivariable logistic regression to quantify as-
sociations between PCP demographic/practice characteris-
tics (independent variables) and the following dependent
variables (a) reported familiarity/utility of CKD guidelines,
(b) agreement with classification of stage 1–2 CKD (i.e.,
eGFR ≥60 ml/min/1.73 m2 and microalbuminuria) in a
non-diabetic individual as representing CKD, and (c) con-
cern regarding overdiagnosis in stage 3a CKD. In regres-
sion modeling, p ≤ 0.1 in univariable analysis was used to
identify factors for inclusion in a multivariable backwards
selection approach. Analyses were performed using Stata
version 13.0 (College Station, TX) and P-values < 0.05
were considered significant.Results
Baseline characteristics
Of the 12,034 PCPs, 45 had nonworking email addresses,
and 11,141 did not open the study emails. Of the 848 re-
cipients who opened a study email, 165 (19.5%) responded
including 14 respondents who partially completed the
survey, answering between 9 and 30 questions each. Re-
spondent characteristics are summarized in Table 1.
Nearly 90% of respondents spent at least half their time
in patient care activities. The majority of respondents
were internists (56%) and generally practiced in an
urban (38%) or suburban (46%) locale. Nearly half of re-
spondents (46%) were part of a private practice. Com-
pared to targeted PCPs, respondents were more likely
to be internists (47% vs 56%, respectively, p = 0.03) and
had graduated medical school more recently (13% vs.
30% within 10 years, 31% vs. 28% between 11 to 20 years,
29% vs. 24% between 21 to 30 years, and 27% vs. 19%
over 30 years ago, respectively, p < 0.001). Respondents
were similar in gender to targeted PCPs (data not shown).
eGFR and albuminuria testing
Following the clinical vignette, 96% of PCPs agreed that
an eGFR was useful in assessing kidney function. In
addition, 72% and 76% of respondents agreed with the
utility of a urine dipstick or a quantitative albuminuria
assessment, respectively. While few respondents (5%) felt
that a urine dipstick would be burdensome to the patient,
20% felt that it would not be helpful due to poor reliability.
In contrast, 30% of PCPs felt a quantitative albuminuria
would be burdensome to the patient and 14% felt it would
not be helpful due to poor reliability.
In non-diabetic hypertensive patients with an eGFR ≥
60 ml/min/1.73 m2, 75% of PCPs reported testing for
albuminuria or proteinuria; 51%, 13%, and 10% of PCPs
reported performing such testing annually, every 2–3
years, and twice a year, respectively. In non-diabetic hyper-
tensive patients with an eGFR < 60 ml/min/1.73 m2, 91%













Family medicine 59 (39.1)
Internal medicine 85 (56.3)






Solo/2 person practice 19 (12.6)
Private group 51 (33.8)
Healthcare organization or HMO 28 (18.5)
University based 31 (20.5)
Government 8 (5.3)
Hospitalist 13 (8.6)
Other (corporate medical) 1 (0.7)
Continuous variables are presented as means with standard deviations.
Categorical variables are expressed as percentages and N.
N = 151 unless otherwise specified. N <165 due to 14 partial respondents who
did not complete the questionnaire.
*N = 131.
Table 2 Barriers to urine albumin/protein testing
endorsed by PCPs
Clinical setting




No impact on management 37 24
Limited time/more urgent patient issues 25 20
Not recommended by guidelines 25 11
Cost 13 9
Poor patient adherence 5 5
Percentages do not sum to 100 as multiple responses were possible.
HTN hypertension, eGFR estimated glomerular filtration rate.
eGFR value in ml/min/1.73 m2.
N = 153.
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55%, 12%, and 22% of PCPs reported performing such
testing annually, every 2–3 years, and twice a year, respect-
ively. Commonly endorsed barriers to urine testing are
shown in Table 2.
CKD definition: agreement and concerns regarding
overdiagnosis
Respondents generally agreed with current guideline-
based CKD definitions (Figure 1). An area where respon-
dents expressed less agreement was in patients with an
eGFR ≥ 60 ml/min/1.73 m2 and “microalbuminuria” (i.e.,
moderate albuminuria). Only 55% of PCPs felt this rep-
resented CKD.
When presented as part of the clinical vignette, 92%
agreed that a chronically reduced eGFR of 50 ml/min/
1.73 m2 represented CKD. However, when asked aboutoverdiagnosis, 30% of PCPs agreed that classifying older
adults with stable eGFRs of 45-59 ml/min/1.73 m2 as
having CKD led to overdiagnosis, while 66% disagreed,
and 4% were uncertain. In contrast, only 5% agreed that
classifying older adults with eGFRs of 30–44 ml/min/
1.73 m2 as having CKD led to overdiagnosis.
ACEi/ARB use: outcome expectancy and barriers
The majority of respondents reported that ACEi/ARBs
would improve outcomes in non-diabetics under a variety
of eGFR and albuminuria categorizations (Table 3). This
included 86% and 77% of PCPs when eGFR was < 60 ml/
min/1.73 m2 and “microalbuminuria” or “macroalbumi-
nuria” was present, respectively (microalbuminuria vs.
macroalbuminuria, p = 0.03).
Commonly endorsed barriers to ACEi/ARB use in non-
diabetics with “macroalbuminuria” were adverse effects
(23%), poor adherence (8%), not recommended by
guidelines (8%), will not improve outcomes (7%), and
more urgent patient issues/limited time (6%).
KDOQI/KDIGO: guideline familiarity
Over half of respondents (Figure 2) reported the KDOQI/
KDIGO guidelines were not helpful in managing their
CKD patients due to a lack of familiarity.
Interventions to enhance CKD care
PCPs were receptive to multiple systematic interventions
to improve their CKD care (Table 4). Excluding continu-
ing medical education (CME), 75% of PCPs supported an
alternative intervention to improve their CKD care.
Association of PCP demographic/practice characteristics
and responses
While adjusting for practice locale in logistic regression
modeling, agreement with the definition of stage 1 or 2
CKD (eGFR ≥ 60 ml/min/1.73 m2 and moderate albumin-
uria) was associated with training in internal medicine (vs.
family medicine, odds ratio [OR] 2.8, 95% confidence
Table 3 Belief that treatment with ACEi/ARBs is beneficial in non-diabetics with the specified characteristics






eGFR ≥ 60 ml/min/1.73 m2 36* 84* 79*
eGFR < 60 ml/min/1.73 m2 63† 86†** 77†**
*eGFR ≥ 60 ml/min/1.73 m2: normal albuminuria vs. moderate or severe albuminuria (p < 0.001).
†eGFR < 60 ml/min/1.73 m2: normal albuminuria vs. moderate or severe albuminuria (p < 0.001).
**eGFR < 60 ml/min/1.73 m2: moderate albuminuria vs. severe albuminuria (p = 0.03).
eGFR estimated glomerular filtration rate.
N = 154.
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medicine (vs. family medicine, OR 2.3, 95% CI 1.1 - 4.7)
associated with reporting that the KDOQI/KDIGO guide-
lines were helpful in managing patients. None of the PCP
characteristics were associated with concerns regarding
overdiagnosis in stage 3a CKD.
Discussion
We found that PCPs overwhelmingly agreed that eGFR
values were helpful. Most also reported testing for albu-
minuria in their non-diabetic hypertensives regardless of
eGFR; however, frequent barriers cited included a lack of
effect on management, limited time, and the perceived
absence of guidelines recommending albuminuria test-
ing. While PCPs expressed very high agreement with the
definition of CKD in patients with marked decrements
in eGFR (eGFR < 45 ml/min/1.73 m2) or decrements in
eGFR coupled with albuminuria, agreement was less ro-
bust when eGFR was > 60 ml/min/1.73 m2 or in CKD
stage 3a without albuminuria. Similarly, a substantial mi-
nority of PCPs were concerned with overdiagnosis in older
adults with an eGFR of 45-59 ml/min/1.73 m2. WhileFigure 2 Responses to “Have the KDOQI/KDIGO CKD guidelines beenmost PCPs felt that ACEi/ARBs improved outcomes in
CKD, even in the absence of albuminuria, agreement with
the potential benefits of ACEi/ARBs was surprisingly high-
est with moderate rather than severe albuminuria. PCPs
reported a lack of familiarity with KDOQI/KDIGO guide-
lines; however, most were receptive to systematic interven-
tions beyond CME to improve their CKD care.
Few have previously examined PCPs’ beliefs, atti-
tudes, and perceived barriers to eGFR reporting, albu-
minuria testing, CKD definitions, and ACEi/ARB use
[30]. Since the publication of the KDOQI guidelines
and the implementation of automated eGFR reporting,
CKD has garnered increasing public and provider at-
tention. Unfortunately, studies have documented lim-
ited improvements in CKD-related processes of care in
recent years, including testing for proteinuria and use
of ACEi/ARBs [7,8,38-41]. Previous surveys suggested
that knowledge deficiencies [12,13,16,17,42] may con-
tribute to continued gaps in care. In contrast to prior
studies where only serum creatinine and proteinuria
were used [16,42], we found that PCPs were relatively
knowledgeable in identifying CKD based on eGFR andhelpful in managing your CKD patients?” N = 151.
Table 4 Potential interventions to enhance CKD care
Intervention to improve CKD care Endorsing PCPs (%)
Continuing medical education 74
EHR decision support 55
Academic detailing by CKD specialist 31
Collaborative practice agreements 29
Audit and feedback 28
None 3
N = 151.
Percentages do not sum to 100 as multiple responses were possible.
CKD chronic kidney disease, PCPs primary care physicians, EHR electronic
health record.
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to isolated albuminuria abnormalities (Figure 1). For ex-
ample, while 99% of PCPs recognized that patients with a
severe reduction in eGFR to 30–44 ml/min/1.73 m2 with
“normoalbuminuria” had CKD, only 84% of PCPs recog-
nized that patients with severe albuminuria and relatively
preserved eGFR had CKD (P < 0.001).
This distinction is clinically important because the
renal benefits of ACEi/ARBs in non-diabetic CKD primar-
ily accrue in severely albuminuric patients [43,44] and the
debated benefits of lower targeted blood pressure in CKD
also primarily apply to albuminuric/proteinuric patients
[45,46]. The under appreciation of the significance of albu-
minuria may be due in part to the greater emphasis on
eGFR in the 2002 KDOQI guidelines. As recent studies
highlight the importance of albuminuria as a marker for
poor outcomes [47-49], initiatives to disseminate this in-
formation and help PCPs understand how to use albumin-
uria to modify their CKD care are needed. The most
frequently cited barrier to testing for albuminuria was that
it would have no impact on management, perhaps because
responding PCPs presumed such patients would already
be receiving ACEi/ARBs. However, recent data suggests
that active ACEi/ARB use is unlikely to fully explain the
low rates of albuminuria/proteinuria testing [7,38,50]. We
suspect limited time and a lack of clarity on how to inte-
grate information regarding albuminuria in developing
non-diabetic CKD care goals is also contributing to low
rates of testing.
Prior studies have documented suboptimal ACEi/ARB
use in CKD patients with proteinuria [10,11]. We found
that most PCPs felt that non-diabetic patients with an
eGFR < 60 ml/min/1.73 m2 would benefit from an ACEi/
ARB regardless of proteinuria. These patterns may be due
in part to greater familiarity with recommendations from
alternative guidelines [51] that favor ACEi/ARB use as first
line treatment in patients with CKD and hypertension
regardless of albuminuria. Of note, similar to prior stud-
ies [15-17], we confirmed low familiarity with KDOQI/
KDIGO CKD guidelines.Our findings support efforts to disseminate the KDIGO
CKD guidelines and to provide PCPs with guidance re-
garding the use of albuminuria and other factors to iden-
tify patients at high risk for poor outcomes [49] and most
likely to benefit from ACEi/ARBs. The most commonly
endorsed barrier to ACEi/ARB use was adverse effects.
Studies are needed to determine whether targeting
high-risk CKD patients who may be more likely to
achieve benefits from these medications [52] could reduce
adverse effects and improve outcomes in older adults with
multiple medications (e.g., NSAIDs, diuretics) [53] com-
pared to other less nuanced recommendations [51,54].
Such an approach could also help PCPs identify a smaller
cohort of ACEi/ARB intolerant patients with a higher like-
lihood to benefit from the use of these medications. In the
setting of severe albuminuria, these individuals may bene-
fit from nephrologist input to determine if alternative
strategies can allow for ACEi/ARB use.
Although a previous survey of PCPs noted patient non-
adherence and the cost of medications as major obstacles
to appropriate care and improving patient outcomes [16],
few respondents in our survey identified these as obstacles
that prevent them from ordering urine albumin tests or
ACEi/ARBs. This may reflect differences in the underlying
populations the responding PCPs serve and changes in the
cost of medications, including the greater availability of
generic ACEi/ARBs.
Many of the barriers we identified are potentially ad-
dressable using systematic interventions. For example, de-
cision support within an electronic health record could
alert a provider as s/he orders a serum creatinine that a
patient with possible CKD does not have a documented
urine albumin test and is not receiving an ACEi/ARB. The
alert could also provide references to guidelines and the
studies that informed those guidelines. Similarly, collab-
orative practice agreements or audit and feedback could
target high-risk CKD patients to ensure they receive op-
timal, evidence-based care. Combining several of these
interventions while targeting patients who are most likely
to benefit from ACEi/ARBs [52] may prove even more im-
pactful. Most PCPs were receptive to at least one of these
approaches and studies are needed to understand whether
such strategies can improve care without substantially dis-
rupting PCP workflow [55].
Our findings should be interpreted in light of several
limitations. First, although we employed best practices
for electronic surveys [37], the survey response rate was
low, which may limit generalizability. Responders may
have substantively differed from non-responders. For ex-
ample, they may have had an interest in kidney disease
and been more knowledgeable than the average PCP.
Respondents were more likely to be internists and had
graduated medical school more recently, characteristics
that may suggest greater familiarity with CKD guidelines
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was modestly higher than in prior PCP survey studies
[12,15,16], although it remained less than 50%. Second,
the majority of targeted PCPs never opened a study
email. While we were able to exclude individuals with
non-valid emails, we could not determine whether an
unopened message was due to an unmonitored email ac-
count, automated filtering into an infrequently checked
folder (e.g., junk), a choice not to open the email based
on the subject matter or sender, or other reasons. In-
cluding individuals with unopened emails would lower
the response rate. Third, PCPs may not have accurately
recalled their practice patterns or may have attempted to
provide what they perceived as the correct answer. To
mitigate this risk, we framed survey questions as asses-
sing beliefs rather than knowledge. Finally, there were
additional questions that would have been helpful to
examine such as the perceived utility of cystatin C [18].
Nevertheless, our findings provide novel information re-
garding PCPs’ beliefs and reported barriers to adoption
of recent CKD practice guidelines. Future work to exam-
ine how local resources, healthcare environments, and pa-
tient characteristics influence providers’ beliefs, perceived
barriers, and practice patterns is warranted.Conclusions
Our survey found that PCPs value eGFR measures and
are able to recognize CKD based on a decrement in
eGFR. However, they were less familiar with albuminuria
abnormalities and endorsed several barriers to testing
for albuminuria in non-diabetics including lack of out-
come expectancy, lack of guideline familiarity, and lack
of time. While PCPs believed that ACEi/ARBs improve
outcomes in various eGFR/albuminuria stages of CKD, fu-
ture interventions will be needed to help operationalize
how to identify patients at high risk for progression and
who are more likely to benefit from ACEi/ARBs. Fortu-
nately, most PCPs appear receptive to interventions to
improve their CKD care.Additional file
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